IL13 and prostate carcinoma: Interestingly, STAT6 inhibitor (AS1517499) has shown some potential in inhibiting prostate cancer cell growth [Table 1; (49)], which opens new possibilities in targeting the IL-4/IL-13 signaling therapeutically even beyond allergic diseases.